Drying of Opzelura® (Ruxolitinib) Cream 1.5%: Implications for Clinical and Real-World Use

Main Article Content

Haydar Abdalghafor
Janel Torsiello
Daniel Sturm
Adnan Nasir
Russell Elliott
Ahmad Naim

Keywords

JAK, Janus Kinase, ruxolitinib

Abstract

 


 

References

1. Persaud I, et al. Int J Pharm. 2020;590:119889

2. Bissonnette R, et al. Rapid, Substantial, and Sustained Reduction of Itch in Adults With Atopic Dermatitis Applying Ruxolitinib Cream: Clinical and Translational Results From the Open-Label Phase 2 SCRATCH-AD Study. Presented at: European Academy of Dermatology and Venereology Congress; October 11-14, 2023; Berlin, Germany

Most read articles by the same author(s)